Sign In  |  Register  |  About Mill Valley  |  Contact Us

Mill Valley, CA
September 01, 2020 1:29pm
7-Day Forecast | Traffic

  • Search Hotels in Mill Valley

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

97.92 -2.78 (-2.76%)
Official Closing Price Updated: 7:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
98 99 Next >
AI Drug Discovery Startups: Analysis Of Exscientia’s Acquisition By Recursion
Exscientia is a European player looking to make a difference in the AI-drug discovery market. Like other players, it has an interesting story to tell. After a brief listing on the stock market,... 
Via Talk Markets
Topics Artificial Intelligence Stocks / Equities
Exposures Artificial Intelligence
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Merck to Hold Fourth-Quarter and Full-Year 2024 Sales and Earnings Conference Call Feb. 4
From Merck & Co., Inc.
Via Business Wire
3 Magnificent S&P 500 Dividend Stocks Down 25%, 60%, and 26% to Buy and Hold Forever
The time to step into quality dividend payers is when the crowd forgets there's never a bad time to own a high-quality stock. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Price Over Earnings Overview: Merck & Co
Via Benzinga
Unpacking the Latest Options Trading Trends in Merck & Co
Via Benzinga
Is NYSE:MRK suited for dividend investing?
Uncovering Dividend Opportunities with MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
What Lies Ahead In 2025? Slower Growth, More Volatility
As we move through 2025, the global economy and financial markets are facing a critical juncture. 
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Economy
Moderna Has Lost 94% Of Its Value Over Four Years. Is It A Sell?
Shares hit another skid on Jan. 13 when the company cut its guidance for 2024 and 2025. 
Via Investor's Business Daily
Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference
JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
NYSE:MRK: good value for what you're paying.
Don't overlook MERCK & CO. INC. (NYSE:MRK)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
2 High-Yield Dividend Stocks to Buy Early in 2025
Via The Motley Fool
Moderna Shares Spike on H5N1 News—What’s Next for Investors?
MRNA stock surged over 12% on growing bird flu concerns; that rally may not last, but analysts believe the company's pipeline makes the stock a Buy in 2025 
Via MarketBeat
Salesforce To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
This Adobe Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Via Benzinga
Merck’s GARDASIL® Receives Expanded Approval for Males in China
From Merck & Co., Inc.
Via Business Wire
2 Reasons to Sell Merck Stock and 1 Reason to Buy
Via The Motley Fool
Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside
Jefferies upgrades Instil Bio to "Buy" with a $52 target, anticipating significant growth for PD-(L)1xVEGF class and SYN2510's potential in cancer treatments. 
Via Benzinga
Merck Buys WuXi Vaccines' Irish Manufacturing Facility For Over $500 Million
MSD acquires WuXi Vaccines' Dundalk facility with a €500 million investment, creating 1,000 new jobs across Ireland and expanding its vaccine production capabilities. 
Via Benzinga
Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst
JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights. 
Via Benzinga
Merck to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Why Viking Therapeutics Stock Plummeted by 24% in December
Via The Motley Fool
Should You Buy the Dip on This High-Flying Stock?
Via The Motley Fool
UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal
Merck's Winrevair (sotatercept) gains UK approval for PAH treatment. Key trial results highlight significant exercise capacity improvements. 
Via Benzinga
Not A Year For The 2024 Dogs Of The Dow
The Dogs of the Dow strategy is one that is focused solely on dividend yield. 
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Dissecting Our Discipline
All portfolio managers practice a stock-picking discipline in which they make choices. 
Via Talk Markets
Topics Stocks / Equities
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
In the Dow Jones Industrial Average, 28 of the 30 components pay dividends. With changes to the components in 2024, dividend yield is smaller overall. 
Via Benzinga
Topics Stocks
Exposures US Equities
Will This Major Pharmaceutical Stock Announce a Stock Split in 2025?
Via The Motley Fool
3 Stocks That Could Be Monster Winners in 2025
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
98 99 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MillValley.com & California Media Partners, LLC. All rights reserved.